Trifluridine and tipiracil

(Lonsurf)

Trifluridine and tipiracil

Drug updated on 11/10/2023

Dosage FormTablet (oral; trifluridine/ tipiracil: 15 mg/6.14 mg, 20 mg/8.19 mg)
Drug ClassAntineoplastics
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • For the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.